Modified Short-Course Radiotherapy Combined With Immunochemotherapy and Targeted Therapy as First-Line Treatment for MSS Metastatic Colorectal Cancer

Conditions

• Patients With Initially Unresectable MSS-type Advanced Colorectal Cancer With Liver and/or Lung and Peritoneal Metastasis

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Receiving lymph node-sparing modified short-course radiotherapy combined with tislelizumab, CAPOX chemotherapy and bevacizumab targeted therapy — DRUG
  Receiving lymph node-sparing modified short-course radiotherapy combined with tislelizumab, CAPOX chemotherapy and bevacizumab targeted therapy

Study Details

This is a single-arm interventional study targeting patients with initially unresectable MSS-type advanced colorectal cancer with liver and/or lung and peritoneal metastasis. Patients will receive lymph node-sparing modified short-course radiotherapy combined with tislelizumab, CAPOX chemotherapy, and bevacizumab targeted therapy, aiming to explore the tumor reactivity and safety of modified short-course radiotherapy combined with immunotherapy and first-line treatment.

Key Dates

First listed

Apr 6, 2026

Start date

Feb 26, 2026

Status verified

Feb 2026

Primary completion

Dec 31, 2026

Completion

Mar 31, 2027

Study Design

Enrollment

33 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: experimental arm
  Lymph node-sparing modified short-course radiotherapy combined with tislelizumab, CAPOX chemotherapy and bevacizumab targeted therapy

Primary Outcome Measure

Objective Response Rate (ORR) [ Time Frame: through study completion, an average of 1 year ]